Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Yung S. Lie, PhD, is the president and CEO of the Damon Runyon Cancer Research Foundation.
Betting on basic science is leading to breakthroughs in immune checkpoint inhibitors, CAR-T, targeted therapies, cancer vaccines and more.
In fact, there are even types of vaccines, known simply as cancer vaccines, that can prevent or potentially treat cancer.
“The simplicity of this approach means that it is promising to take forward” to a human vaccine, researchers say.
Many vaccines are preventive. This is a THERAPEUTIC vaccine: it teaches your immune system to recognize the problem AFTER you have it.
The vaccine, based on an individual’s own tumor cells, improved survival time and proved safe in an early-stage trial.
INVAC-1 vaccine targets the telomerase enzyme involved in cancer cell growth.
Vaccine has the potential to prevent 90 percent of HPV-related cancers.
Customized immunotherapy targets receptor found in some breast, colorectal, lung, ovarian, prostate and gastroesophageal cancers.
Matthias Stephan, MD, PhD, receives grant to develop cancer vaccine–optimizing, TCR-programming nanotechnology.
Future clinical trials will explore whether cellular and antibody-based therapies can be beneficial as earlier-stage treatments.
As our understanding of the molecular basis of disease rises, doctors and researchers gain greater insight into individual patient needs.
Activating T cells in tumors eliminated even distant metastases in mice, Stanford researchers found.
More than 40 percent of cancers are caused by factors we can control.
Individually tailored vaccines help T cells recognize tumors.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.